Skip to main content

Advertisement

Table 3 Net and incremental benefits from the government use licenses, comparing public health expenditure prior to and after the government use licenses

From: Government use licenses in Thailand: an assessment of the health and economic impacts

Drugs Treatment No of patients increased access to drug
(%)
Increased productivity
(Million USD)
Health expenditure (Million USD) Net Benefit
(Million
USD)
Incremental Benefit
(Million USD) (%)
EFV 1st line ARV 17,959
(21.3%)
309 97 212 67.0
(50.6%)
NVP    301 156 145  
LPV/r 2nd line ARV 3,421
(4.0%)
8.6 6.9 1.7 2.3
(1.7%)
IDV/r    8.6 9.2 -0.6  
Clopidogrel+ASA 2nd prevention of ischemic events 40,947
(48.7%)
870.6 0.9 869.7 5.7
(4.3%)
ASA only    864.1 0.1 864.0  
Letrozole Breast Cancer Hormone therapy 8,916
(10.6%)
343 2 341 12.0
(9.1%)
Tamoxifen    332 3 329  
Docetaxel Breast Cancer Chemo therapy 5,958
(7.1%)
14.6 1.3 13.3 12.5
(9.5%)
Paclitaxel    11.1 10.3 0.8  
Docetaxel Lung Cancer Chemo therapy 4,855
(5.8%)
5.6 0.8 4.8 25.7
(19.4%)
Pemetrexed    5.6 26.5 -20.9  
Erlotinib Lung Cancer Chemo therapy 256
(0.3%)
0.3 0.6 -0.3 -*
Gifitinib    N/A N/A N/A  
Imatinib CML Chemo therapy 1,293
(1.5%)
4.1 -** 4.1 7.2
(5.4%)
  GIST Chemo therapy 553
(0.7%)
3.1 -** 3.1  
Total 84,158
(100%)
    132.4
(100%)
  1. * Erlotinib: no data available to assess the incremental benefit
  2. ** Imatinib: no data on cost of drug as patients receive access to the drug free under GIPAP